molecular, biology, symposium, Bordet, cancer, brussels

You are here: Medical Info

Meetings

Molec. Biology Advances into Oncology Clin. practic

Medical Meetings, Lectures...

Fifth Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice

FIFTH BELGIAN SYMPOSIUM ON THE
INTEGRATION OF MOLECULAR BIOLOGY ADVANCES INTO ONCOLOGY CLINICAL PRACTICE

Friday November 25, 2011

and Saturday November 26, 2011

Organizing Committee:

Institut Jules Bordet

A. AWADA
E. DE AZAMBUJA

M. PICCART-GEBHART

BSMO

J. DE GRÈVE/L. DIRIX

R. PARIDAENS

J.P. MACHIELS

Location:Hotel Golden Tulip, Bessenveldstraat 15, Diegem, Belgium

FRIDAY 25 AFTERNOON

13.30 - 14.00

Arrival – coffee and tea

14.00 - 14.10

Welcome
R. Paridaens (UZ, Leuven) - A. Awada (Jules Bordet, Belgium)

14.10 – 14.30
Chair: P. Flamen
(Jules Bordet, Belgium)

Why and how early response to chemotherapy in solid tumors should be documented?

Speaker: A. Hendlisz (Jules Bordet, Belgium)

14.30 – 15.30
Chair: R. Paridaens
(KUL Leuven, Belgium)

Histology beyond diagnosis of cancer:

Role of Ki67 and other biomarkers in breast cancer stratification and as surrogate marker of tumor response

Speaker: . Dowsett (Royal Marsden, U.K.)

Immunohistochemistry of primary tumor versus metastasis and role in the treatment management
Speaker: Jonas Bergh (Karolinska, Sweden)

15.30-16.00

Coffee Break

16.00 – 17.00
Debate
Chair: L. Dirix
(AZ St Augustinus, Wilrijk)

Molecular-targeted agents as unique therapeutic approach in solid tumors: is it a reality?

DEBATE :

HER-2 therapies in breast cancer
Speaker: M. Piccart (Jules Bordet, Belgium)

Inhibiting genetic drivers of carcinogenesis in NSCLC
Speaker: J. de Grève (VUB, Belgium)

17.00 – 18.00
Chair: A. Awada
(Jules Bordet, Belgium)

Emerging biological therapies in solid tumors :

Melanoma - Speaker : V. Cocquyt (UZ Gent, Belgium)
Prostate - Speaker : JP Machiels (UCL, Belgium)
Sarcoma - Speaker : B. Kasper (Maanheim University, Deutschland)
Thyroid - Speaker : Y. Lalami (Jules Bordet, Belgium)

SATURDAY 26 MORNING

8.30 – 9.00

Arrival – coffee and tea

9.00 – 10.00
Chair: R. Salgado
(AZ St Augustinus, Wilrijk,

Jules Bordet, Belgium)

Why tumor escape to targeted therapies is a fatality : a pathological and biological view
Speaker: J. Fletcher (Havard Cancer Center Boston, USA)

10.00 – 10.30
Chair: H. Wildiers
(KUL Leuven, Belgium)

The future of PARP inhibitors
Speaker: Andrew Tutt (Guy’s& St Thomas hospital, UK)

10.30-11.00

Coffee Break

11.00 – 11.30
Chair: J.L. Canon
(GHdC, Charleroi)

Targeted chemotherapy: an old dream, a new reality
Speaker: J. Kerger (UCL Mont Godinne, Belgium)

11.30 – 12.00
Chair: J. Kerger
(UCL, Belgium)

Maintenance therapy revisited : the example of NSCLC
Speaker: T. Berghmans (Jules Bordet, Belgium)

12.00 - 13.10
Chair: J. Klastersky
(Jules Bordet, Belgium)

Side effects of molecular-targeted therapies and management

- Skin
Speaker: S. Segaert (KUL Leuven, Belgium)

- Cardio-vascular
Speaker: E. de Azambuja (Jules Bordet, Belgium)

- Benefit risk and cost-effectiveness of targeted agents
Speaker: R. Crott (UCL, Belgium)

13.10

Closing remarks followed by a light lunch
R. Paridaens (UZ, Leuven) - A. Awada (Jules Bordet, Belgium)

Meeting language: English
CME accreditation: Ethics and economy accreditation requested
For further information please contact Ms. Mariella Gonzalez at the following e-mail address: mariella.gonzalez@bordet.be